Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

NCT04089059 · View on ClinicalTrials.gov ↗

Study Summary

This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).

Interventions

  • DEVICE Cordella™ Pulmonary Artery Sensor System

Study Locations (20)

California

  • Loma Linda University — Loma Linda
  • Eisenhower Medical Center — Rancho Mirage
  • UCSD — San Diego
  • Kaiser San Francisco — San Francisco
  • UCSF Medical Center — San Francisco
  • Kaiser Santa Clara — Santa Clara

Florida

  • Baptist Health South Florida — Miami
  • Ascension Sacred Heart — Pensacola
  • USF Health — Tampa
  • Cleveland Clinic — Weston

Illinois

  • Northwestern — Chicago
  • U of Chicago — Chicago
  • Heart Centers of Illinois — Palos Park

Alabama

  • Ascension St Vincent's — Birmingham
  • Huntsville Hospital — Huntsville

Arizona

  • Phoenix Cardiovascular Research Group/Insight — Phoenix

Colorado

  • South Denver Cardiology — Littleton

Connecticut

  • Hartford Hospital — Hartford

Georgia

  • Piedmont Athens — Athens

Trial Details

FieldValue
Enrollment Target 738 participants
Start Date 2020-01-10
Est. Completion 2028-04
Phase NA

Sponsor

Endotronix

34 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04089059

The ClinicalTrials.gov registry entry for NCT04089059 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 738 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endotronix, which has 34 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Heart Failure NYHA Class III appearing as the primary indexed condition, and to 1 intervention — of which Cordella™ Pulmonary Artery Sensor System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04089059 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04089059 about?

NCT04089059 is a clinical study titled "PROACTIVE-HF IDE Trial Heart Failure NYHA Class III". This is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).

What is the current status of trial NCT04089059?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 738 participants. The study started on 2020-01-10. Estimated completion is 2028-04.

What conditions does trial NCT04089059 study?

This clinical trial studies the following conditions: Heart Failure NYHA Class III. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04089059?

The interventions under investigation include: Cordella™ Pulmonary Artery Sensor System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04089059?

This trial is sponsored by Endotronix, which has 34 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04089059 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial